跳至主要内容
临床试验/NL-OMON53525
NL-OMON53525尚未招募2 期

Imaging inflammation in Alzheimer*s Disease - InflamAD

Amsterdam UMC0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Group 1: subjects along the AD continuum
  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • 1. Be along the AD continuum, defined as having positive biomarker evidence
  • (CSF or PET) for the presence of Aβ pathology.
  • 2. At least 50 years of age;
  • 3. Subjects must, in the opinion of the principal investigator/attending
  • neurologist, be able to tolerate study procedures and be competent to make a
  • well-informed decision to participate in this study;
  • 4. Signed informed consent for Amsterdam Dementia Cohort (2016.061);
  • Group 2: cognitively unimpaired subjects
  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria:
  • 1. Have biomarker evidence (CSF or PET) for the absence of Aβ pathology;
  • 2. Have no objective cognitive impairment as determined by a neuropsychologist
  • or neuropsychological testing;
  • 3. At least 50 years of age;
  • 4. Subjects must, in the opinion of the principal investigator/attending
  • neurologist, be able to tolerate study procedures and be competent to make a
  • well-informed decision to participate in this study.
  • 5. Signed informed consent for Amsterdam Dementia Cohort (2016.061);

排除标准

  • 1. Has contra indications for MRI scanning and therefore cannot receive a brain
  • 2. Has evidence of (gross) structural abnormalities such as major stroke or
  • mass on MRI that is likely to interfere with interpretation of PET scan;
  • 3. Inability to undergo PET-CT with administration of radioligand [11C]SMW139;
  • 4. Is a woman of childbearing potential who is not surgically sterile, not
  • refraining from sexual activity or not using reliable methods for
  • contraception. Women of childbearing potential must not be pregnant or breast
  • feeding at screening and at imaging;
  • 5. Has a relevant history of severe drug allergy or hypersensitivity. This
  • includes (but is not limited to) hay fever, allergies to cats and dogs, and
  • dust mite allergy. Other relevant severe drug allergies or hypersensitivities
  • should be evaluated by the Principal Investigator;
  • 6. Has ever participated in an experimental study with a tau, amyloid or
  • neuroinflammation targeting agent, unless it can be documented that the subject
  • received only placebo during the course of the trial;
  • 7. History of any clinically significant cardiovascular, endocrinology,
  • hematologic, hepatobiliary, immunologic, inflammatory, metabolic, urologic,
  • pulmonary (including asthma), neurologic (with the exception of AD),
  • psychiatric, renal or other major disease, as determined by the principal
  • investigator;
  • 8. In male subjects Hb < 8.0 g/dL, in female subjects Hb < 7.0 g/dL;
  • 9. Has been injected with a previously administered radiopharmaceutical within
  • 6 terminal half-lives OR when total yearly radiation exposure exceeds 10 mSv;
  • 10. Has a history of severe traumatic brain injury (TBI);
  • 11. The following medications during the study and 4 weeks prior to [11C]SMW139
  • a. Use of anticonvulsant medications;
  • b. Anti-inflammatory medications (e.g. chronic NSAID use);
  • c. Other medications that, in the opinion of the investigator, may interfere
  • with the study.

研究者

发起方
Amsterdam UMC

相似试验